Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Mar;43(3):1073-1082.
doi: 10.1007/s10067-024-06865-z. Epub 2024 Jan 11.

Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study

Mihribangvl Alip  1 , Dandan Wang  1 , Shengnan Zhao  1 , Siqi Li  1 , Dongdong Zhang  1 , Xiaoxiao Duan  1 , Shiying Wang  1 , Bingzhu Hua  1 , Hong Wang  1 , Huayong Zhang  1 , Xuebing Feng  1 , Lingyun Sun  2
Affiliations
Comparative Study

Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study

Mihribangvl Alip et al. Clin Rheumatol. 2024 Mar.

Abstract

Objective: To assess the long-term safety and efficacy of umbilical cord mesenchymal stem cells transplantation (UMSCT) in patients with systemic sclerosis (SSc).

Methods: Forty-one patients with moderate to severe SSc underwent UMSCT at the Affiliated Drum Tower Hospital of Nanjing University Medical School from 2009 to 2017. In this study, we conducted a longitudinal and retrospective analysis and compared the clinical and laboratory manifestations before and after UMSCT. The main outcome of the study was overall survival. We evaluated changes in the modified Rodnan Skin Score (mRSS), as well as the changes in the pulmonary examination by using high-resolution computed tomography (HRCT) and ultrasound cardiogram (UCG). Additionally, we assessed the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the severity of peripheral vascular involvement during the first year after treatment.

Results: The overall 5-year survival rate was 92.7% (38 out of 41 patients). Following UMSCT, the mean mRSS significantly decreased from 18.68 (SD = 7.26, n = 41) at baseline to 13.95 (SD = 8.49, n = 41), 13.29 (SD = 7.67, n = 38), and 12.39 (SD = 8.49, n = 38) at 1, 3, and 5 years, respectively. Improvement or stability in HRCT images was observed in 72.0% of interstitial lung disease (ILD) patients. Pulmonary arterial hypertension (PAH) remained stable in 5 out of 8 patients at the 5-year follow-up. No adverse events related to UMSCT were observed in any of the patients during the follow-up period.

Conclusion: UMSCT may provide a safe and feasible treatment option for patients with moderate to severe SSc based on long-term follow-up data. The randomized controlled study will further confirm the clinical efficacy of UMSCT in SSc.

Clinical trial registration: ClinicalTrials.gov Identifier: NCT00962923. Key Point • UMSCT is safe and effective for SSc patients.

Keywords: Efficacy; Long-term safety; Systemic sclerosis; Umbilical cord mesenchymal stem cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909 - DOI - PubMed
    1. Denton CP, Khanna D (2017) Systemic sclerosis. Lancet (London, England) 390(10103):1685–1699. https://doi.org/10.1016/S0140-6736(17)30933-9 - DOI - PubMed
    1. Hachulla E, Launay D (2011) Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 40(2):78–83. https://doi.org/10.1007/s12016-010-8198-y - DOI - PubMed
    1. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620–628. https://doi.org/10.1136/ard.2008.096677 - DOI - PubMed
    1. Velier M, Daumas A, Simoncini S, Arcani R, Magalon J, Benyamine A, Granel B et al (2021) Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis. Bone Marrow Transplant. https://doi.org/10.1038/s41409-021-01492-7 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources